Developer docs
API playgroundTry for free, no card

Search company profiles

i-Cognitio Sciences

Full company profile

uuid00bxphp

Namestring
i-Cognitio Sciences
Legal namestring
i-Cognitio Sciences
Websiteurl
i-cognitio.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

i-Cognitio Sciences is a Hong Kong-based medical technology company that develops AI-powered retinal imaging analysis software for early detection of Alzheimer's disease and cognitive decline. The company's core product, RetinAD 1.0, applies machine learning models trained on a proprietary multi-ethnic dataset of over 16,000 retinal images to triage individuals at risk for Alzheimer's dementia and to flag those with suboptimal control of modifiable risk factors such as hypertension and diabetes. The platform is delivered as a cloud-based SaaS solution with disclosed performance of 90% specificity and 94% sensitivity in distinguishing Alzheimer's dementia from cognitively normal subjects, validated through internal and external tests.

The company was founded by three professors from The Chinese University of Hong Kong (CUHK) — Vincent Mok (neurology), Carol Cheung (ocular imaging), and Owen Ko (AI/medical technology) — and is privately held with no disclosed funding rounds. RetinAD 1.0 is deployed through B2B enterprise sales and OEM-embedded channels, including alliances with retinal camera manufacturers for hardware-level integration and a partnership with Humansa to distribute screening to AIA Hong Kong's Alta Club membership programme for high-net-worth customers.

Revenue mechanics center on SaaS platform licensing (subscription/recurring) and B2B enterprise licensing to healthcare providers, clinics, hospitals, optical shops, body-check centers, and longevity programme providers. Pricing is quote-based and not publicly disclosed. The company targets two primary segments — healthcare providers (vertical) and insurers/longevity service providers — with a secondary segment of health-conscious individuals for primary prevention. Future plans include mobile app integration and product expansion into diabetic retinal disease, glaucoma, and broader dementia diagnosis.

Short descriptiontext

i-Cognitio Sciences is a Hong Kong-based medical AI company that provides RetinAD 1.0, a cloud-based SaaS platform using retinal imaging and machine learning to triage Alzheimer's and cognitive decline risk for healthcare providers, insurers, and longevity programmes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTuen Mun, Hong Kong SAR China
HQ citystring
Tuen Mun
HQ countrystring
Hong Kong SAR China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI healthcare diagnostics, retinal imaging analysis, brain health assessment, Alzheimer's screening software, medical imaging SaaS
Industry1 code
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Software Publishers5132
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Computer Integrated Systems Design7373
Product category
AI Healthcare Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS Platform Licensing
TypeSubscription Recurring
Description

Cloud-based SaaS subscription model providing brain health assessment services to healthcare providers, clinics, hospitals, and other medical organizations. Scalable per-assessment or subscription-based pricing for B2B customers.

i-cognitio.com
2B2B Enterprise Licensing
TypeLicensing Royalties
Description

Licensing of RetinAD platform to strategic partners including retinal camera manufacturers and healthcare organizations for integration into their medical settings and screening initiatives.

i-cognitio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1RetinAD 1.0
Description

AI-powered non-invasive assessment of brain health and Alzheimer's risk using retinal imaging analysis. Achieves 94% sensitivity and 90% specificity in distinguishing Alzheimer's dementia from cognitive normal subjects.

i-cognitio.com
Core offering1 text field

i-Cognitio Sciences develops and sells RetinAD 1.0, a cloud-based AI software platform that analyzes retinal images to triage individuals at risk of Alzheimer's dementia and identify suboptimal control of modifiable risk factors. The platform is offered as a SaaS subscription and through enterprise licensing to healthcare providers, clinics, hospitals, optical shops, longevity programmes, and insurance partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90% specificity and 94% sensitivity in distinguishing Alzheimer's dementia from cognitive normal subjects
+3 more records
Product overview1 text field

i-Cognitio Sciences offers a single core product called RetinAD 1.0, an AI-powered non-invasive brain health assessment platform. The platform leverages retinal imaging analysis combined with machine learning algorithms to detect early signs of Alzheimer's dementia and cognitive decline. The technology provides a triage mechanism to identify individuals who may benefit from further in-depth evaluations, and is offered as a cloud-based SaaS solution with future plans to expand into diabetic retinal disease, glaucoma, and broader dementia diagnosis.

Product and service1 record
1RetinAD 1.0
CategoryAI healthcare diagnostics software
Description

AI-powered non-invasive brain health assessment platform that analyzes retinal images to triage individuals at risk for Alzheimer's dementia and identify cognitively normal individuals with suboptimal control of modifiable risk factors such as hypertension, diabetes, and lifestyle habits. Designed for healthcare providers, clinics, hospitals, optical shops, body-check centers, longevity programmes, and insurance partners.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-02
Description

Strategic collaboration with Humansa for deployment of AI-powered retinal imaging brain health screening solution. Humansa serves as healthcare service provider enabling distribution to AIA Hong Kong's Alta Club membership programme, reaching high-net-worth customers seeking cognitive health assessment.

2Sengital Limited
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with industry leader Sengital Limited to develop and bring innovative AI-driven ocular imaging solutions to the forefront of medical diagnostics. Collaboration empowers the company to integrate advanced technology into commercial products.

i-cognitio.com
3Major Retinal Camera Manufacturers
Strategic tierCoreTypeTechnology or Integration
Description

Strategic alliances with leading retinal camera manufacturers to integrate RetinAD platform with cutting-edge ocular imaging hardware. These partnerships ensure widespread deployment and usability of the AI-powered brain health assessment tool across diverse medical settings globally.

i-cognitio.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic alliances with healthcare organizations for enhanced reach and impact. RetinAD is integrated into diverse medical settings from local clinics and specialized centers to global screening initiatives, maximizing the tool's impact on global health through primary prevention.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Altoida uses AI-driven digital biomarkers (including cognitive and functional assessments) for early detection of Alzheimer's disease, competing in the same neurodegeneration risk-assessment space.

TypeOthers
Description

AIA Hong Kong is i-Cognitio's anchor enterprise customer and distribution partner through the Alta Club programme, illustrating the insurer-led channel model i-Cognitio aims to replicate with other payers.

TypeDirect peer
Description

BrainCheck delivers cognitive assessment software for clinicians to detect and manage cognitive impairment and dementia, serving a similar provider customer base as i-Cognitio.

TypeDirect peer
Description

Neurotrack develops digital cognitive health assessments for early detection of Alzheimer's and cognitive decline, targeting similar enterprise healthcare and consumer wellness use cases as i-Cognitio.

5Sengital Limited
TypeOthers
Description

Sengital is both a strategic partner and an adjacent ocular imaging hardware/commercial player; its broader ocular imaging solutions portfolio overlaps with the retinal imaging infrastructure that RetinAD depends on.

TypeDirect peer
Description

Cogstate provides computerised cognitive testing and brain health assessment tools used by clinicians, researchers, and pharmaceutical trials, overlapping with i-Cognitio's cognitive screening and risk-stratification positioning.

TypeDirect peer
Description

RetiSpec is a direct competitor using AI-driven retinal imaging to detect Alzheimer's disease and other neurodegenerative conditions, making it the closest functional and technical peer to i-Cognitio's RetinAD platform.

TypeDirect peer
Description

Cambridge Cognition offers digital cognitive assessment platforms for clinical trials, healthcare, and research, addressing the same neurodegenerative disease screening market as RetinAD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

i-Cognitio Sciences

AI Healthcare Diagnosticsi-cognitio.com

i-Cognitio Sciences is a Hong Kong-based medical AI company that provides RetinAD 1.0, a cloud-based SaaS platform using retinal imaging and machine learning to triage Alzheimer's and cognitive decline risk for healthcare providers, insurers, and longevity programmes.

What i-Cognitio Sciences does

i-Cognitio Sciences is a Hong Kong-based medical technology company that develops AI-powered retinal imaging analysis software for early detection of Alzheimer's disease and cognitive decline. The company's core product, RetinAD 1.0, applies machine learning models trained on a proprietary multi-ethnic dataset of over 16,000 retinal images to triage individuals at risk for Alzheimer's dementia and to flag those with suboptimal control of modifiable risk factors such as hypertension and diabetes. The platform is delivered as a cloud-based SaaS solution with disclosed performance of 90% specificity and 94% sensitivity in distinguishing Alzheimer's dementia from cognitively normal subjects, validated through internal and external tests.

The company was founded by three professors from The Chinese University of Hong Kong (CUHK) — Vincent Mok (neurology), Carol Cheung (ocular imaging), and Owen Ko (AI/medical technology) — and is privately held with no disclosed funding rounds. RetinAD 1.0 is deployed through B2B enterprise sales and OEM-embedded channels, including alliances with retinal camera manufacturers for hardware-level integration and a partnership with Humansa to distribute screening to AIA Hong Kong's Alta Club membership programme for high-net-worth customers.

Revenue mechanics center on SaaS platform licensing (subscription/recurring) and B2B enterprise licensing to healthcare providers, clinics, hospitals, optical shops, body-check centers, and longevity programme providers. Pricing is quote-based and not publicly disclosed. The company targets two primary segments — healthcare providers (vertical) and insurers/longevity service providers — with a secondary segment of health-conscious individuals for primary prevention. Future plans include mobile app integration and product expansion into diabetic retinal disease, glaucoma, and broader dementia diagnosis.

i-Cognitio Sciences firmographics

Firmographics
Name
i-Cognitio Sciences
Legal name
i-Cognitio Sciences
Website
https://i-cognitio.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
i-Cognitio Sciences is a Hong Kong-based medical AI company that provides RetinAD 1.0, a cloud-based SaaS platform using retinal imaging and machine learning to triage Alzheimer's and cognitive decline risk for healthcare providers, insurers, and longevity programmes.
Ownership category
akta.pro rank

i-Cognitio Sciences industry classification

Industry
Product category
AI Healthcare Diagnostics
NAICS
Software Publishers (5132), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • AI healthcare diagnostics
  • Retinal imaging analysis
  • Brain health assessment
  • Alzheimer's screening software
  • Medical imaging SaaS

Where i-Cognitio Sciences is headquartered

Location

Headquarters

HQ city
Tuen Mun
HQ country
Hong Kong SAR China
HQ region
Asia

Offices1 record

Markets served

i-Cognitio Sciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. SaaS Platform Licensing: Cloud-based SaaS subscription model providing brain health assessment services to healthcare providers, clinics, hospitals, and other medical organizations. Scalable per-assessment or subscription-based pricing for B2B customers.
  2. B2B Enterprise Licensing: Licensing of RetinAD platform to strategic partners including retinal camera manufacturers and healthcare organizations for integration into their medical settings and screening initiatives.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

i-Cognitio Sciences product offering

Product offering

Core offering

i-Cognitio Sciences develops and sells RetinAD 1.0, a cloud-based AI software platform that analyzes retinal images to triage individuals at risk of Alzheimer's dementia and identify suboptimal control of modifiable risk factors. The platform is offered as a SaaS subscription and through enterprise licensing to healthcare providers, clinics, hospitals, optical shops, longevity programmes, and insurance partners.

Product overview

i-Cognitio Sciences offers a single core product called RetinAD 1.0, an AI-powered non-invasive brain health assessment platform. The platform leverages retinal imaging analysis combined with machine learning algorithms to detect early signs of Alzheimer's dementia and cognitive decline. The technology provides a triage mechanism to identify individuals who may benefit from further in-depth evaluations, and is offered as a cloud-based SaaS solution with future plans to expand into diabetic retinal disease, glaucoma, and broader dementia diagnosis.

Differentiator

Problem solved

Functional benefit

Brands

  • RetinAD 1.0: AI-powered non-invasive assessment of brain health and Alzheimer's risk using retinal imaging analysis. Achieves 94% sensitivity and 90% specificity in distinguishing Alzheimer's dementia from cognitive normal subjects.

Products and services

  • RetinAD 1.0 AI-powered non-invasive brain health assessment platform that analyzes retinal images to triage individuals at risk for Alzheimer's dementia and identify cognitively normal individuals with suboptimal control of modifiable risk factors such as hypertension, diabetes, and lifestyle habits. Designed for healthcare providers, clinics, hospitals, optical shops, body-check centers, longevity programmes, and insurance partners.

Quantifiable outcome

  • 90% specificity and 94% sensitivity in distinguishing Alzheimer's dementia from cognitive normal subjects
  • +3 more outcomes

Companies that use i-Cognitio Sciences

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

i-Cognitio Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

i-Cognitio Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • HumansacoreChannel Partner/ Reseller/ Distributor · 2 March 2026Strategic collaboration with Humansa for deployment of AI-powered retinal imaging brain health screening solution. Humansa serves as healthcare service provider enabling distribution to AIA Hong Kong's Alta Club membership programme, reaching high-net-worth customers seeking cognitive health assessment.
  • Sengital LimitedcoreStrategic or Co-development PartnerStrategic partnership with industry leader Sengital Limited to develop and bring innovative AI-driven ocular imaging solutions to the forefront of medical diagnostics. Collaboration empowers the company to integrate advanced technology into commercial products.
  • Major Retinal Camera ManufacturerscoreTechnology or IntegrationStrategic alliances with leading retinal camera manufacturers to integrate RetinAD platform with cutting-edge ocular imaging hardware. These partnerships ensure widespread deployment and usability of the AI-powered brain health assessment tool across diverse medical settings globally.
  • Healthcare OrganizationscoreChannel Partner/ Reseller/ DistributorStrategic alliances with healthcare organizations for enhanced reach and impact. RetinAD is integrated into diverse medical settings from local clinics and specialized centers to global screening initiatives, maximizing the tool's impact on global health through primary prevention.

Scale indicators5 records

Recent moves5 records

Expansion highlights3 records

i-Cognitio Sciences competitors and assessment

Company assessment

Direct peers

  • Altoida: Altoida uses AI-driven digital biomarkers (including cognitive and functional assessments) for early detection of Alzheimer's disease, competing in the same neurodegeneration risk-assessment space.
  • BrainCheck: BrainCheck delivers cognitive assessment software for clinicians to detect and manage cognitive impairment and dementia, serving a similar provider customer base as i-Cognitio.
  • Neurotrack Technologies: Neurotrack develops digital cognitive health assessments for early detection of Alzheimer's and cognitive decline, targeting similar enterprise healthcare and consumer wellness use cases as i-Cognitio.
  • Cogstate: Cogstate provides computerised cognitive testing and brain health assessment tools used by clinicians, researchers, and pharmaceutical trials, overlapping with i-Cognitio's cognitive screening and risk-stratification positioning.
  • RetiSpec: RetiSpec is a direct competitor using AI-driven retinal imaging to detect Alzheimer's disease and other neurodegenerative conditions, making it the closest functional and technical peer to i-Cognitio's RetinAD platform.
  • Cambridge Cognition: Cambridge Cognition offers digital cognitive assessment platforms for clinical trials, healthcare, and research, addressing the same neurodegenerative disease screening market as RetinAD.

Others

  • AIA Hong Kong: AIA Hong Kong is i-Cognitio's anchor enterprise customer and distribution partner through the Alta Club programme, illustrating the insurer-led channel model i-Cognitio aims to replicate with other payers.
  • Sengital Limited: Sengital is both a strategic partner and an adjacent ocular imaging hardware/commercial player; its broader ocular imaging solutions portfolio overlaps with the retinal imaging infrastructure that RetinAD depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

i-Cognitio Sciences social profiles

Digital presence

i-Cognitio Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

i-Cognitio Sciences leadership team

Management profile

Number of profiles

Profiles3 records

i-Cognitio Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

i-Cognitio Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i-Cognitio Sciences

What does i-Cognitio Sciences do?

i-Cognitio Sciences develops and sells RetinAD 1.0, a cloud-based AI software platform that analyzes retinal images to triage individuals at risk of Alzheimer's dementia and identify suboptimal control of modifiable risk factors. The platform is offered as a SaaS subscription and through enterprise licensing to healthcare providers, clinics, hospitals, optical shops, longevity programmes, and insurance partners.

Is i-Cognitio Sciences a public or private company?

i-Cognitio Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was i-Cognitio Sciences founded?

i-Cognitio Sciences was founded in -1. It employs 1 to 10 people.

Where is i-Cognitio Sciences based?

i-Cognitio Sciences is headquartered in Tuen Mun, Hong Kong SAR China, in the Asia region.

How does i-Cognitio Sciences make money?

Two revenue lines are on record. SaaS Platform Licensing is the primary driver. The others are B2B Enterprise Licensing.

Who are i-Cognitio Sciences's main competitors?

Direct peers on record are Altoida, BrainCheck, Neurotrack Technologies, Cogstate, RetiSpec and Cambridge Cognition. Others are AIA Hong Kong and Sengital Limited.

Does i-Cognitio Sciences have an API?

No public API is recorded for i-Cognitio Sciences.

What industry is i-Cognitio Sciences in?

i-Cognitio Sciences's product category is AI Healthcare Diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 5132 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Media-outreachAIA Alta Club Launches Brain Health ProgrammeAIA Alta Club, an exclusive membership programme for high-net-worth customers by AIA Hong Kong, launched the Brain Health Programme featuring the world's first AI-powered retinal imaging technology for early detection of cognitive decline, making AIA Hong Kong the first insurer in the market to offer this screening solution. The technology, developed by i-Cognitio Sciences (a research company originating from The Chinese University of Hong Kong) and launched through collaboration with Humansa, provides a non-invasive retinal scan with up to 92% accuracy, combined with personalised coaching and science-backed wellness plans. The programme aims to address cognitive health as a core pillar of healthspan, with research indicating up to 45% of dementia cases can be prevented or delayed with early detection.ZawyaAIA Alta Club Launches Brain Health ProgrammeAIA Alta Club launched a Brain Health Programme featuring a world-first AI-driven retinal scan for early detection of cognitive decline. The non-invasive scan has up to 92% accuracy and is developed by i-Cognitio Sciences, with personalized coaching and wellness plans. The programme aims to prevent dementia, which costs around HK$200,000 annually in Hong Kong.Media-outreachHumansa and i-Cognitio Sciences Unveil the World’s First AI-Powered Retinal Imaging for Alzheimer’s Risk DetectionHumansa launched its BrainSpark Program with i-Cognitio Sciences, using AI retinal imaging to detect Alzheimer's risk. The model, validated on 13,000 fundus photos, achieved 80-92% accuracy. The program offers personalized lifestyle interventions for early prevention.